Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V. Moosmann N, et al. Among authors: schalhorn a. J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7. J Clin Oncol. 2011. PMID: 21300933 Clinical Trial.
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Heinemann V, et al. Among authors: schalhorn a. J Clin Oncol. 2006 Aug 20;24(24):3946-52. doi: 10.1200/JCO.2005.05.1490. J Clin Oncol. 2006. PMID: 16921047 Clinical Trial.
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Köhler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermüller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V. Fischer von Weikersthal L, et al. Among authors: schalhorn a. Eur J Cancer. 2011 Jan;47(2):206-14. doi: 10.1016/j.ejca.2010.09.022. Eur J Cancer. 2011. PMID: 20971632 Clinical Trial.
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Giessen C, Stintzing S, Laubender RP, Ankerst DP, Schulz C, Moosmann N, Modest DP, Schalhorn A, von Weikersthal LF, Heinemann V. Giessen C, et al. Among authors: schalhorn a. Clin Colorectal Cancer. 2011 Dec;10(4):317-24. doi: 10.1016/j.clcc.2011.03.027. Epub 2011 May 12. Clin Colorectal Cancer. 2011. PMID: 21729676 Clinical Trial.
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V. Modest DP, et al. Among authors: schalhorn a. Anticancer Drugs. 2014 Feb;25(2):212-8. doi: 10.1097/CAD.0000000000000041. Anticancer Drugs. 2014. PMID: 24201305 Clinical Trial.
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials.
Stahler A, Stintzing S, Modest DP, Ricard I, Giessen-Jung C, Kapaun C, Ivanova B, Kaiser F, Fischer von Weikersthal L, Moosmann N, Schalhorn A, Stauch M, Kiani A, Held S, Decker T, Moehler M, Neumann J, Kirchner T, Jung A, Heinemann V. Stahler A, et al. Among authors: schalhorn a. Clin Cancer Res. 2020 Dec 15;26(24):6559-6567. doi: 10.1158/1078-0432.CCR-20-2748. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943459
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Held S, von Einem JC, Holch J, Neumann J, Kirchner T, Jung A, Modest DP. Stahler A, et al. Among authors: schalhorn a. Int J Cancer. 2016 Feb 1;138(3):739-46. doi: 10.1002/ijc.29807. Epub 2015 Sep 18. Int J Cancer. 2016. PMID: 26284333
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Stahler A, Heinemann V, Neumann J, Crispin A, Schalhorn A, Stintzing S, Giessen-Jung C, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Holch JW, Kruger S, Haas M, Michl M, von Einem J, Kirchner T, Jung A, Modest DP. Stahler A, et al. Among authors: schalhorn a. Anticancer Drugs. 2017 Aug;28(7):717-722. doi: 10.1097/CAD.0000000000000510. Anticancer Drugs. 2017. PMID: 28582279 Clinical Trial.
105 results